Tafamidis 80 mg is more likely to improve disease measures than placebo in patients with transthyretin amyloid cardiomyopathy
Hanna M, Angeli FS, Zhang RY, Crespo-Leiro M
ISA 2024
- 国际淀粉样变学会年会 2024
| 罕见病 | 转甲状腺素蛋白淀粉样变性
Differences in cardiac nuclear imaging results with 99mTc-DPD, 99mTc-PYP, and 99mTc-HMDP bone radiotracers in patients with left ventricular hypertrophy of unknown etiology screened for transthyretin amyloid cardiomyopathy in the TTRACK study
Haro del Moral FJ, Garcia-Pavia P, Munteanu C, Keohane D, Mallaina P, Damy T, Itti E
ISA 2024
- 国际淀粉样变学会年会 2024
| 罕见病 | 转甲状腺素蛋白淀粉样变性
Trends in Diagnostic Testing in Medicare Patients With Wild-Type Transthyretin Cardiac Amyloidosis
Pankratova C, Chung H, Gutierrez C, Rava A, Sienko D, Swarup S, Ebrahim A, Witteles R
ISA 2024
- 国际淀粉样变学会年会 2024
| 罕见病 | 转甲状腺素蛋白淀粉样变性
Social Determinants of Health-Related Disparities in the Diagnosis of Transthyretin Cardiac Amyloidosis
Pankratova C, Chung J , Crowley A, Rava A, Sienko D, Boame N, Swarup S, Ebrahim A, Alexander K
ISA 2024
- 国际淀粉样变学会年会 2024
| 罕见病 | 转甲状腺素蛋白淀粉样变性
Prevalence of transthyretin amyloid cardiomyopathy in patients with hypertrophic cardiomyopathy: Final analysis of the TTRACK study
Piriou N, Elliott P, Damy T, Barriales Villa R, Cappelli F, Munteanu C, Bahus C, Keohane D, Mallaina P, García-Pavía P
ISA 2024
- 国际淀粉样变学会年会 2024
| 罕见病 | 转甲状腺素蛋白淀粉样变性
Predictors of burden in caregivers to patients with untreated transthyretin amyloid cardiomyopathy
Ponti L, Hsu K, Damy T, Villacorta E, Verheyen N, Keohane D, Wang R, Ines M, Kumar N, Munteanu C, Cappelli F
ISA 2024
- 国际淀粉样变学会年会 2024
| 罕见病 | 转甲状腺素蛋白淀粉样变性
International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction
Yun S, Palladini G, Anderson L, Cariou E, Wang R, Angeli F, Garcia-Pavia P
ISA 2024
- 国际淀粉样变学会年会 2024
| 罕见病 | 转甲状腺素蛋白淀粉样变性
